This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article a pharmacist with significant experience in the area of finance identifies and discusses five common financial mistakes to avoid as a pharmacist. . Authored By: Timothy Ulbrich, PharmD. Co-Founder and CEO of Your Financial Pharmacist (YFP). Article posted 21 June 2022. While financial mistakes may seem inevitable, some do not have to be.
Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of the disease transthyretin amyloidosis (ATTR) it licensed from Ionis in a $3.6 billion deal last year. Eplontersen – previously known as IONIS-TTR-LRX – is designed to switch off the production of transthyretin (TTR), a protein which builds up in the disease to toxic levels causing heart problems (cardiomyopathy) and nerve damage (polyneuropathy).
Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their populations, the pharma industry has called the proposals “unnecessary and harmful to innovation”. Proposals to waive COVID-19 product patents have been described as “political posturing” and an “answer to a problem that does not exist”.
Alzheimer’s disease could be diagnosed from a single MRI brain scan, according to a new study by Imperial College London. Using machine learning technology, researchers were able to examine structural features of the brain, including regions that are not traditionally associated with Alzheimer’s. The simplicity of this process, scientists suggest, could aid clinicians in identifying the disease at an early stage when it can be challenging to diagnose.
Alzheimer’s disease could be diagnosed from a single MRI brain scan, according to a new study by Imperial College London. Using machine learning technology, researchers were able to examine structural features of the brain, including regions that are not traditionally associated with Alzheimer’s. The simplicity of this process, scientists suggest, could aid clinicians in identifying the disease at an early stage when it can be challenging to diagnose.
If new restrictions are placed on the FDAâs Accelerated Approval pathway, as many as two thirds of the treatments that use this pathway would never reach patients, according to research released at the BIO International Convention last week.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Do you know a Pharmacist with a North Dakota License? Our journey to Fargo, North Dakota began when one of our clients forwarded an email to our team asking if there was anyone who knew a pharmacist with a North Dakota license. Innocently, and perhaps naively, Todd Raehtz, President of Indispensable Health , replied to the email that he had personally received the multistate pharmacist passport in response to the COVID-19 pandemic and North Dakota was among the participating states.
When choosing a 3PL whether for a new product launch in the near future or re re-evaluating your current situation, certain key considerations must be addressed before you make a final decision.
uMotif and ClinOne announced at the 2022 DIA Global Annual Meeting that they have partnered to deliver an integrated solution for eCOA and eConsent in trials.
Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more joined-up services for their locality in England from 1 July 2022 – will touch on every issue that is shaping healthcare today. “A lot of things are happening in the environment right now and all of the key issues at the national level are relevant at the sub-national – ICS – level.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
When choosing a 3PL whether for a new product launch in the near future or re re-evaluating your current situation, certain key considerations must be addressed before you make a final decision.
40
40
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content